Levodopa/Carbidopa/Entacapone Lannacher

Levodopa/Carbidopa/Entacapone, the active ingredient in Levodopa/Carbidopa/Entacapone Lannacher, is an antiparkinson agent presented as an oral tablet for oral use. It is used to manage the motor symptoms of Parkinson's disease in adults.

GNH USA supplies Levodopa/Carbidopa/Entacapone Lannacher as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is an antiparkinson combination that targets dopamine deficiency in Parkinson's disease.

Parkinson's disease: improves motor symptoms and reduces "off" periods. Parkinson's disease with motor fluctuations: prolongs the clinical effect of levodopa. Advanced Parkinson's disease: helps maintain functional mobility and daily activities.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions.

Common Side Effects: - Nausea or vomiting - Orthostatic hypotension - Dyskinesia (involuntary movements) - Dry mouth - Insomnia or vivid dreams - Diarrhea or abdominal discomfort

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Severe hypertension or hypertensive crisis - Cardiac arrhythmias - Severe liver enzyme elevation - Allergic reactions such as rash, angioedema, or anaphylaxis - Psychiatric disturbances including hallucinations or confusion

Levodopa/Carbidopa/Entacapone requires careful monitoring due to its pharmacologic profile.

Dose adjustments: titrate gradually to balance symptom control and side‑effects. Cardiovascular monitoring: watch for orthostatic hypotension and hypertension. Psychiatric assessment: monitor for hallucinations, confusion, or mood changes. Renal or hepatic impairment: consider dose modification or increased surveillance. Pregnancy and lactation: use only if the potential benefit justifies the potential risk. Store at ambient temperature: keep below 25 °C, retain in the original container, protect from moisture and light.

Levodopa/Carbidopa/Entacapone interacts with several drug classes that can alter its efficacy or safety.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics with strong dopamine blockade: may diminish therapeutic effect. - High‑dose vitamin B6 (pyridoxine): can reduce levodopa availability.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may exacerbate orthostatic hypotension. - Iron or calcium supplements: can impair levodopa absorption; separate dosing by at least 2 hours. - SSRIs or SNRIs: may increase risk of serotonin syndrome when combined with MAO‑B inhibitors.